Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

NCT07040332 | Recruiting

• 1 other identifier: QFS-2025-074
• Study Type: observational
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.

Conditions

Allergic Bronchopulmonary Aspergillosis (ABPA)

Outcome Measures

Primary Outcomes (1)

• Total serum IgE

  Up to 12 months

Secondary Outcomes (2)

• Aspergillus-specific IgE

  Up to 12 months

• Aspergillus-specific IgG

  Up to 12 months

Study Arms (3)

allergic bronchopulmonary aspergillosis

fungal-sensitized asthma

control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The patients with allergic bronchopulmonary aspergillosis and fungal-sensitized asthma who were treated in several hospitals were included as the study objects, and the relatively normal ones who had no bronchial asthma and no fungal sensitization were matched by gender and age as the control group, and then the cohorts of patients with allergic bronchopulmonary aspergillosis, fungal-sensitized asthma and the control group were established.

You may qualify if:

• Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.
• Meets the diagnostic criteria for fungal-sensitized asthma.

You may not qualify if:

• Human immunodeficiency virus infection.
• Malignant tumor.
• Blood system disease.
• autoimmune system disease.
• History of pulmonary tuberculosis.
• Patients with a history of smoking or still smoking.
• Invasive pulmonary fungal disease.
• Contraindications electronic bronchoscopy

Sponsors & Collaborators

• Qianfoshan Hospital: lead
• Shanghai Pulmonary Hospital, Tongji University School of Medicine: collaborator
• Fudan University: collaborator
• Guizhou Provincial People's Hospital: collaborator
• The First Hospital of Jilin University: collaborator
• Qilu Hospital of Shandong University: collaborator

Study Sites (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

Jinan, Shandong, 250014, China

RECRUITING

MeSH Terms

Conditions

Aspergillosis, Allergic Bronchopulmonary

Condition Hierarchy (Ancestors)

Pulmonary Aspergillosis; Aspergillosis; Mycoses; Bacterial Infections and Mycoses; Infections; Lung Diseases, Fungal; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Qian Qi, Prof.

CONTACT

+86 13706380314; qiqianqlh@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: June 11, 2025
• First Posted: June 27, 2025
• Study Start: May 10, 2025
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): January 31, 2029
• Last Updated: July 4, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)